WAVEGATE NEWS

Lake Charles, LA — January 14, 2026 — Wavegate Corporation today announced that Jeff Cambra has joined the company as Chief Executive Officer, effective January 14, 2026. Mr. Cambra brings more than 28 years of senior leadership experience across medical devices, combination products, and biopharmaceuticals, with a proven track record of building organizations, scaling operations, advancing regulatory programs, and driving global commercialization.

Wavegate Corporation is developing next-generation spinal cord stimulation technologies designed to deliver more precise, adaptive, and patient-specific neuromodulation therapies. Mr. Cambra’s appointment reflects the company’s transition into its next phase of growth, as it advances its platform toward clinical validation, regulatory engagement, and eventual commercialization.

Mr. Cambra most recently served as Chief Executive Officer of SpinaFX, an early-stage medical device company focused on minimally invasive, image-guided therapies for back pain. During his tenure, he led the company through multiple stages of growth, raised more than CAD $29 million…

LAKE CHARLES, La., Jan. 13, 2022 /PRNewswire/ -- Wavegate Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its StimuLux™ optical reflectometry system for closed-loop adaptive modulation of spinal cord stimulation. The FDA's Breakthrough Device designation is designed to expedite the development and regulatory review of medical devices that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary evidence must demonstrate a reasonable expectation that the device will provide improved effectiveness compared to the standard of care.

"We are pleased the FDA has granted Breakthrough Device designation for our novel StimuLux™ technology. This underscores the urgent need within our society for more effective treatments of chronic, debilitating pain," said Erich Wolf, MD, PhD, Chief Executive Officer. "We are eager to closely collaborate with the FDA as Wavegate works toward advancing the state of the art."

StimuLux™ is a…

April 23, 2020- Lake Charles, LA. Wavegate Technologies, LLC, has been restructured as a Delaware C-corporation. This gives Wavegate Corporation additional flexibility in stock offerings to investors and provides a widely-accepted legal framework under Delaware law.

Wavegate is pleased to announce that Matt F. Thomas has joined Wavegate's Board of Directors. Matt brings deep domain experience to Wavegate, having served as the General Manager for Medtronic's Spinal Cord Stimulation business. Matt is a welcome addition to the senior management team at Wavegate and rounds out the executive experience required to navigate Wavegate's Ellipse platform to the best-in-class market leader.

Matt Thomas has over 25 years of experience leading medical device businesses. He has broad experience in strategy, business development, marketing, sales & new product development. Prior to joining Cerapedics in 2020, Matt was Vice President & General Manager for Medtronic’s Spinal Cord Stimulation & Early Interventions pain business. Previously, Matt also led a turnaround of Medtronic’s Kyphon business, returning it to growth for the first time since the acquisition. He joined Medtronic in 2002 and also had leadership roles in spine, diabetes, and deep brain stimulat…